Tag archive for ‘Neuralstem, Inc.’
SmithOnStocks Opines on Stocks May 19, Edition
One Approach for Investing in Emerging Biotechnology Stocks I write on biotechnology and pharmaceutical companies of all sizes, but I have spent much of the last year focusing on small biotechnology companies ranging in size from as low as $50 million in market capialization.to about $400 million. There is much less analyst and investor attention […]
Neuralstem: Update on ALS Trial Could be a Catalyst for the Stock (CUR, $1.30)
Key Investment Summary The lead investigator will give an important update on the ALS phase I trial on Friday, May 17 that will have meaningful efficacy data on eight patients and safety data on fourteen. I believe that the paper will be positive based on highly encouraging results already reported for five patients. I also […]
Neuralstem: Anticipating More Efficacy Data from ALS Trial (CUR, $1.18)
Investment Opinion and Thesis I am continuing to recommend purchase of Neuralstem. The Company has completed its first trial in humans, a 15 patient phase I trial in amyotrophic lateral sclerosis or ALS. Results of this trial have indicated that the surgical procedure used to implant the cells and the cells themselves are safe, which […]
Initiating Coverage of Neuralstem with a Buy (CUR, $0.92)
Product Development Overview This report provides an introduction to stem cells and the cells that comprise the central nervous system. Basic knowledge of both is needed to understand the investment thesis for Neuralstem. Its technology platform is based on first isolating neural stem cells from fetal tissue and then expanding them in cell cultures to […]